Financial Performance - The company's revenue for the third quarter reached ¥369,133,140.66, representing a year-on-year increase of 35.24%[4] - Net profit attributable to shareholders was ¥70,028,170.48, a significant increase of 619.37% compared to the same period last year[4] - The basic earnings per share (EPS) was ¥0.5921, reflecting a growth of 607.53% year-on-year[4] - Total operating revenue for the current period reached ¥867,669,135.00, an increase of 17.99% compared to ¥735,466,949.07 in the previous period[16] - The net profit for the current period was ¥16,843,870.49, a significant recovery from a net loss of ¥34,034,829.25 in the previous period[17] - The operating profit for the current period was ¥16,943,532.89, compared to an operating loss of ¥33,862,682.30 in the prior period[17] - The company reported a basic earnings per share of ¥0.1384, recovering from a loss per share of ¥0.3017 in the previous period[17] - The company recorded a total comprehensive income of ¥16,843,870.49, compared to a total comprehensive loss of ¥34,034,829.25 in the previous period[17] Cash Flow and Liquidity - The net cash flow from operating activities was ¥165,750,904.80, an increase of 131.97% compared to the previous year[4] - Cash flow from operating activities generated a net amount of ¥165,750,904.80, an increase from ¥71,453,388.10 in the previous period[18] - Cash and cash equivalents increased to ¥482,153,455.98 from ¥361,137,972.25, representing a growth of approximately 33.5%[13] - Cash and cash equivalents at the end of the period totaled ¥475,493,515.61, up from ¥336,854,042.32 at the end of the previous period[19] - The company’s short-term borrowings and other current liabilities were not specified, indicating a stable liquidity position[14] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥2,356,732,077.33, up 2.22% from the end of the previous year[4] - Total assets reached ¥2,356,732,077.33, up from ¥2,305,515,184.73, reflecting a growth of approximately 2.2%[15] - Total liabilities increased to ¥799,565,513.00 from ¥786,123,172.76, marking a rise of about 1.6%[15] - The company's equity attributable to shareholders rose to ¥1,530,286,947.58 from ¥1,492,022,748.07, showing an increase of approximately 2.6%[15] - The company’s retained earnings increased to ¥454,044,080.61 from ¥437,710,562.97, reflecting a growth of approximately 3.0%[15] Inventory and Investments - The company reported a total of ¥206,992,668.61 in inventory, up from ¥196,073,298.03, which is an increase of about 5.0%[13] - The company’s long-term investments in fixed assets amounted to ¥1,395,775,574.46, slightly up from ¥1,364,751,902.73, indicating a growth of about 2.3%[14] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 10,290[10] - The company has not reported any changes in the number of preferred shareholders or any significant changes in shareholding structure[12] Government Support and Financial Expenses - The company received government subsidies amounting to ¥560,903.95 during the reporting period[6] - The company reported a decrease in financial expenses by 171.13% due to new project usage rights amortization[8] - The company incurred financial expenses of ¥5,572,591.42, which is an increase from ¥2,055,286.82 in the prior period[16] Mergers and Acquisitions - The company did not execute any mergers or acquisitions during the reporting period[20]
华绿生物(300970) - 2025 Q3 - 季度财报